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ABSTRACT: Currently, no information is available on the effect of resistance/susceptibility to
first-line drugs different from isoniazid and rifampicin in determining the outcome of extensively
drug-resistant tuberculosis (XDR-TB) patients, and whether being XDR-TB is a more accurate
indicator of poor clinical outcome than being resistant to all first-line anti-tuberculosis (TB) drugs.
To investigate this issue, a large series of multidrug-resistant TB (MDR-TB) and XDR-TB cases
diagnosed in Estonia, Germany, Italy and the Russian Federation during the period 1999–2006
were analysed. Drug-susceptibility testing for first- and second-line anti-TB drugs, quality
assurance and treatment delivery was performed according to World Health Organization
recommendations in all study sites.
Out of 4,583 culture-positive TB cases analysed, 361 (7.9%) were MDR and 64 (1.4%) were XDR.
XDR-TB cases had a relative risk (RR) of 1.58 to have an unfavourable outcome compared with
MDR-TB cases resistant to all first-line drugs (isoniazid, rifampicin ethambutol, streptomycin and,
when tested, pyrazinamide), and an RR of 2.61 compared with ‘‘other’’ MDR-TB cases (those
susceptible to at least one first-line anti-TB drug among ethambutol, pyrazinamide and
streptomycin, regardless of resistance to the second-line drugs not defining XDR-TB).
The emergence of extensively drug-resistant tuberculosis confirms that problems in
tuberculosis management are still present in Europe. While waiting for new tools which will
facilitate management of extensively drug-resistant tuberculosis, accessibility to quality
diagnostic and treatment services should be urgently ensured and adequate public health
policies should be rapidly implemented to prevent further development of drug resistance.
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xtensively drug-resistant tuberculosis
(XDR-TB) is defined as resistance to at
least rifampin (R) and isoniazid (H; this is
the definition of multidrug-resistant tuberculosis
(MDR-TB)), in addition to any fluoroquinolone,
and at least one of the three injectable anti-
tuberculosis (TB) drugs (capreomycin, kanamycin
and amikacin). The XDR-TB definition was made
on the assumption that these classes of drugs are
essential to successfully treat a case of TB,
although evidence of its clinical relevance was
not available at the time [1–4].
In a preliminary analysis of European patients,
the current authors recently demonstrated higher
probability of death and worse outcomes in
XDR-TB cases when compared with MDR-TB
cases [5].
Previous studies demonstrated that among MDR-
TB cases the probability of achieving treatment
success varies, depending on the number of first-
line drugs the patient is susceptible to [6].
However, it is not known whether XDR-TB is a
more accurate indicator of poor clinical outcome
than being resistant to all first-line anti-TB drugs
[6]. In fact, there is no information available on
the effect of resistance/susceptibility to first-line
drugs different from HR in determining the
outcome of XDR-TB patients. To investigate this
issue a larger series of MDR-TB and XDR-TB
cases diagnosed in Western and Eastern
European countries was analysed.
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METHODS
Data from all culture confirmed TB cases diagnosed consecu-
tively by the TB clinical reference centres in Estonia (Tallin and
Tartu), Germany (Borstel, Grosshansdorf and Bad-
Lippspringe), Italy (Sondalo, Milan and Rome) and a North-
Eastern region of the Russian Federation (Archangels Oblast)
were analysed.
Clinical outcomes (available on the original clinical records)
were measured as part of an ad hoc study performed in the
previously mentioned countries during the period 1999–2006
(Italy and Germany: 2003–2006; Estonia: 2001–2004; Archangels
Oblast: 1999–2001) [5, 7, 8]. Drug-susceptibility testing (DST) for
first- and second-line anti-TB drugs was performed according
to World Health Organization (WHO) recommendations by
quality-assured laboratories and was re-tested at the WHO’s
Supranational Reference Laboratories (Rome/Milan, Borstel,
Stockolm and Oslo) [9, 10]. In Italy, Germany and Estonia the
BACTECTM MGIT 960TM TB System (Becton Dickinson
Diagnostic Systems, Sparks, MD, USA) was used to test first-
line drugs and the proportion method on Lowenstein–Jensen
was used to test second-line drugs in all centres. In Archangels
Oblast the proportion method on Lowestein–Jensen medium
was used. In Oslo, DST for both first- and second-line drugs
was carried out using the BACTEC 460 TB System (Becton
Dickinson Diagnostic Systems).
In all countries, regimens to treat MDR-TB and XDR-TB cases
were tailored to the DST results according to WHO recom-
mendations, the main categories of second-line drugs being
generally available to treat patients during the study period
(injectable agents: amikacin, capreomycin and kanamycin;
fluoroquinolones; second-line oral agents: ethionamide/
prothionamide; para-aminosalycilic acid and cycloserine).
Third-line agents (e.g. amoxicillin/clavulanicacid, clarithromy-
cin, clofazimine) were not available in Archangels Oblast.
MDR-TB cases resistant to all first-line drugs were defined as
those resistant to H, R, ethambutol, streptomycin and, when
tested, pyrazinamide. Other MDR-TB cases were those
susceptible to at least one first-line anti-TB drug among
ethambutol, pyrazinamide and streptomycin (regardless of
resistance to the second-line drugs not defining XDR-TB).
Outcomes were compared using the Chi-squared test (catego-
rical variables) in cases achieving a final outcome (different
from default, transferred out and still on treatment), and using
the Kaplan–Meier curve where appropriate.
RESULTS
Out of 4,583 culture-positive TB cases analysed (Italy: 2,140;
Germany: 748; Estonia: 900; Archangels Oblast: 795), 361 (7.9%)
were MDR (Italy: 83; Germany: 43; Estonia: 194; Archangels
Oblast: 41) and 64 (1.4%) were XDR (Italy: 8; Germany: 3;
Estonia: 53; Archangels Oblast: 0). In Italy, 1.46% of all the
notified culture-positive cases were MDR (4.2% in the present
study); in Germany, 2.1% of culture-positive cases were MDR
(6.1% in the present study); in Estonia they were 27.4% and in
Archangels Oblast 5.2%, as all cases were included in the study.
In total, 178 (49.3%) out of 361 MDR-TB cases and 48 (75%) out
of 64 XDR-TB cases were re-treatment cases (p,0.001). Out of
341 MDR-TB cases tested for HIV, 17 (5%) were HIV infected, as
were two (3.2%) out of the 61 XDR-TB cases. Out of 361 MDR-
TB cases, 267 (74%) were resistant to all first-line drugs, 51
(14.1%) were resistant to H, R and streptomycin, 19 (5.3%) to H,
R and ethambutol, and 24 (6.6%) to HR.
Out of 64 XDR-TB cases, none were resistant to HR only, one
case was resistant to fluoroquinolone and one was resistant to
injectable drugs. A total of 58 (90.6%) were resistant to all first-
line drugs, (plus, eventually, other second-line drugs) and 6
(9.4%) were resistant to HR plus ethambutol or streptomicin
and/or other second-line drugs.
Included in the outcome analysis were 240 MDR-TB cases (187
were resistant to all first-line drugs) and 48 XDR-TB cases
achieving a final outcome.
XDR-TB cases were more likely to be resistant to all first-line
drugs than MDR-TB cases (p,0.005). The cases excluded from
the analysis were equally distributed among groups. Patients
still receiving treatment were as follows. XDR-TB: eight out of
64; MDR-TB resistant to all first-line drugs: 38 out of 267; other
MDR: 31 out of 94. Patients who defaulted/transferred out
were as follows. XDR-TB: eight out of 64; MDR-TB resistant to
all first-line drugs: 42 out of 267; other MDR: 10 out of 64.
No difference in the profile of drug resistance for second-line
drugs was found among the groups analysed, excluding the
XDR-defining second-line drugs (XDR-TB: mean 1.3, median 1;
MDR-TB resistant to all first-line drugs: mean 1.3, median 1;
other MDR-TB: mean 0.8, median 1). Details on outcomes by
resistance pattern are summarised in table 1.
At the univariate analysis, XDR-TB cases had significantly
worse outcomes than MDR-TB cases resistant to all first-line
drugs and other MDR-TB cases.
XDR-TB cases had a relative risk (RR) of 1.58 to have an
unfavourable outcome compared with MDR-TB cases resistant
to all first-line drugs (95% confidence interval (CI) 1.14–2.20, 26
out of 48 versus 64 out of 187; p,0.05) and an RR of 2.61 (95%
CI 1.45–4.69, 26 out of 48 versus 11 out of 53; p,0.001)
compared with other MDR-TB cases.
MDR-TB cases resistant to all first-line drugs were more likely
to have an unfavourable outcome than other MDR-TB cases
(death or failure: 64 out of 187 versus 11 out of 53, RR 1.65, 95%
CI 0.94–2.89), although the difference was not significant at the
conventional p 0.05 level (p50.06). The difference was
statistically significant if patients still on treatment were not
removed from the analysis (64 out of 225 versus 11 out of 84;
p,0.01). This analysis is performed under the assumption that
the patients still on regular treatment will achieve a successful
treatment outcome. If the opposite is assumed, i.e. that all
patients still on treatment achieve an unsuccessful treatment
outcome, no greater statistically significant difference is
detected between the two groups. The difference in treatment
outcomes among the three groups also remains significant
after adjusting for age and country of diagnosis.
Using the Kaplan–Meier analysis, the time to treatment success
is significantly different among the three groups, with the
lowest rate of treatment success in the XDR-TB group
(p,0.005; fig 1).
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DISCUSSION
This is the first study to show in a large cohort from four
European countries, at low HIV prevalence, that XDR-TB cases
have a clinical outcome worse than MDR-TB cases resistant to
all first-line anti-TB drugs, and that susceptibility to one or
more first-line drugs increases the probability to treat success-
fully MDR-TB cases. The results also demonstrate the possible
existence of a ‘‘continuum’’ of severity in terms of clinical
outcome among XDR-TB, MDR-TB resistant to all first-line
drugs and other MDR-TB cases.
The results of the current study, which are consistent with
those of a recently performed laboratory-based survey [8],
show the following. 1) XDR-TB cases with a resistance pattern
strictly corresponding to the definition (e.g. H, R, one
fluoroquinolone and one injectable drug) are not frequently
identified in the clinical practice, as second-line drugs are
introduced when drug resistance to all first-line drugs is likely
to have occurred. 2) The occurrence of XDR-TB, as currently
defined, has both a clinical value (predicting poor outcome)
and an operational significance (confirming the loss of first-line
drugs coupled with key second-line drugs).
Limitations of the study include the following. First, the
observation that data are representative in only two of the
settings surveyed (Estonia and Archangels Oblast). In Italy and
Germany the prevalence of MDR-TB in TB clinical reference
centres is higher than the prevalence detected at national level.
Secondly, since 16.4% of patients were lost to follow-up, their
outcome is not well characterised. Thirdly, the difference in
outcomes between MDR-TB resistant to all first-line drugs
versus other MDR-TB cases reached only borderline signifi-
cance under the assumption that patients still receiving regular
treatment will reach a successful outcome. In the current
authors’ opinion this assumption is more likely to represent
the truth than the opposite, i.e. that all patients still on
treatment will have an unsuccessful outcome. Due to the
difficulty in raising large numbers on a relatively uncommon
form of disease, such as MDR-TB/XDR-TB, global studies will
be necessary to give a final answer to this question.
Finally, although DST for second-line drugs in the present study
were quality controlled by WHO Supranational Reference
Laboratories, some caution is always needed when interpreting
results in relation to XDR-TB. Although protocols to standardise
DST for second-line drugs are presently being developed,
universally accepted proficiency testing does not exist.
The fact that the results from Italy and Germany [5] remain
consistent after including data from Eastern European coun-
tries suggests that the study results are robust. The negative
impact of TB treatment mismanagement (and suboptimal
infection control in congregate settings) [5, 11] in selecting
resistant mutants in Europe is further confirmed by the
observation that 75 and 49.3% of XDR-TB and MDR-TB cases,
respectively, were previously treated for TB.
Further information on extensively drug-resistant tuberculosis
will hopefully be available in the next few years when
surveillance systems will be equipped to identify all the
existing extensively drug-resistant tuberculosis cases and to
TABLE 1 Outcomes of extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB) cases in
Estonia, Germany, Italy and the Russian Federation
Treatment success Died Default Failure Transferred Total patients
completing treatment
XDR-TB# 22 (39.3) 14 (25.0) 8 (14.3) 12 (21.4) 0 (0.0) 56
MDR-TB resistant to all
first-line drugs"
123 (53.7) 35 (15.3) 39 (17.0) 29 (12.7) 3 (1.3)
229
Other MDR-TB+ 42 (66.7) 8 (12.7) 10 (15.9) 3 (4.8) 0 (0.0) 63
Total 187 (53.7) 57 (16.4) 57 (16.4) 44 (12.6) 3 (0.9) 348
Data are presented as n (%) or n. #: resistance to at least rifampin and isoniazid (definition of MDR-TB) in addition to any fluoroquinolone, and at least one of the three
injectable anti-TB drugs (capreomycin, kanamycin and amikacin); ": cases resistant to isoniazid, rifampicin ethambutol, streptomycin and, when tested, pyrazinamide;
+: cases susceptible to at least one first-line anti-TB drug. Default and transferred cases included in this table were removed from the analysis presented in the text.
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FIGURE 1. A Kaplan–Meier plot showing estimated proportion of treatment
success (cure plus treatment completion) according to the drug-resistance profile
in Estonia, Germany, Italy and the Russian Federation. ????????: other mutidrug-
resistant tuberculosis (MDR-TB) cases; - - - - -: MDR-TB cases resistant to all first-
line drugs; –––––: extensively drug-resistant tuberculosis cases.
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monitor their risk factors and outcomes [11]. At the same time,
the emergence of extensively drug-resistant tuberculosis
confirms that problems in tuberculosis management are still
present in Europe. While waiting for new tools that will
facilitate the management of extensively drug-resistant tuber-
culosis, accessibility to quality diagnostic and treatment
services should be urgently ensured and adequate public
health policies should be rapidly implemented to prevent
further development of drug resistance.
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